The estimated Net Worth of Peter Radovich is at least $2.54 Milión dollars as of 25 March 2024. Mr Radovich owns over 4,303 units of Mirum Pharmaceuticals Inc stock worth over $1,215,935 and over the last 9 years he sold MIRM stock worth over $798,421. In addition, he makes $524,849 as Chief Operating Officer at Mirum Pharmaceuticals Inc.
Mr has made over 11 trades of the Mirum Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 4,303 units of MIRM stock worth $111,017 on 25 March 2024.
The largest trade he's ever made was exercising 30,000 units of Mirum Pharmaceuticals Inc stock on 23 January 2018 worth over $48,300. On average, Mr trades about 2,272 units every 85 days since 2015. As of 25 March 2024 he still owns at least 29,013 units of Mirum Pharmaceuticals Inc stock.
You can see the complete history of Mr Radovich stock trades at the bottom of the page.
Peter Radovich M.B.A., Ph.D. is the Chief Operating Officer at Mirum Pharmaceuticals Inc.
As the Chief Operating Officer of Mirum Pharmaceuticals Inc, the total compensation of Mr D at Mirum Pharmaceuticals Inc is $524,849. There are 6 executives at Mirum Pharmaceuticals Inc getting paid more, with Christopher Peetz having the highest compensation of $6,235,180.
Mr D is 43, he's been the Chief Operating Officer of Mirum Pharmaceuticals Inc since . There are 17 older and 2 younger executives at Mirum Pharmaceuticals Inc. The oldest executive at Mirum Pharmaceuticals Inc is Michael Grey, 67, who is the Chairman of the Board.
Peter's mailing address filed with the SEC is C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY, CA, 94404.
Over the last 5 years, insiders at Mirum Pharmaceuticals Inc have traded over $10,912,565 worth of Mirum Pharmaceuticals Inc stock and bought 7,735,045 units worth $117,972,829 . The most active insiders traders include Forest Baskett, Scott D Sandell a Anthony A. Jr. Florence. On average, Mirum Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of $4,538,937. The most recent stock trade was executed by Patrick J Heron on 6 September 2024, trading 230 units of MIRM stock currently worth $9,563.
mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.
Mirum Pharmaceuticals Inc executives and other stock owners filed with the SEC include: